LOS ANGELES--(BUSINESS WIRE)--June 15, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI - News), an integrated, global biopharmaceutical company, today said it will host an R&D Investor Day on Tuesday, June 20, 2006 in New York, New York. Senior management will be in attendance and will present an overview of the company’s pipeline and platform technologies, including updates on the ABRAXANE® oncology clinical program, including Phase 3 trials, the COROXANE(TM) cardiovascular clinical program, the nab(TM) technology platform with discussions about SPARC, and first-in-class technologies.
